-
JAMA: Supplementing with a daily multivitamin reduces total cancer incidence
CHICAGO — In a randomized trial that included nearly 15,000 male physicians and started in 1997, long-term daily multivitamin use resulted in a modest, but statistically significant, reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA that was released Wednesday. The multivitamin used in the study was Pfizer's Centrum Silver.
-
Successful Australian VMS marketer to launch in the U.S. market January 2013
VICTORIA, Australia — Sales of Swisse Ultivite multivitamins in the Australian and Asian markets have been a big driver behind overall sales, according to a Nielsen report cited by the company.
Across both Australia and Asia, VMS sales were up 16% to $197 million for the year ended June 2012. Leading the charge was Suisse Ultivite, which grew by more than 40% "thanks to a high ad spend and launches that boost the profile of the whole range,” Nielsen said.